Type:
Educational Exhibit
Authors:
M. Kirchin1, G. Pirovano2, N. Shen2, U. Halemane2, C. Venetianer2, J. R. Parker2, C. Schultz2, A. Spinazzi2; 1Milan/IT, 2Princeton, NJ/US
DOI:
10.1594/ecr2008/C-318
Conclusions
Gadobenate dimeglumine demonstrates unique benefits for many clinical applications. The higher r1 relaxivity of gadobenate dimeglumine permits increased contrast enhancement and greater diagnostic information compared to standard-relaxivity agents at equivalent dose, and offers the potential for accurate diagnostic performance with lower doses. Over the past decade many clinical studies, both inter- and intraindividual, have demonstrated improved performance for gadobenate dimeglumine when compared to conventional Gd contrast agents for many routine MR applications. Published data from clinical trials and postmarketing surveillance have confirmed the excellent safety profile of gadobenate dimeglumine.